Iceland· IS-EU/1/22/1675/002

Tecvayli

A teclistamab product containing teclistamabum inn, registered in Iceland by Janssen-Cilag International NV*. The same ATC class is registered in 14 of our 19 countries.

ATC L01FX24

Checked against Icelandic Medicines Agency (Iceland) on

Informational only — not a medical device.

SOURCE REGISTER · ISIcelandic Medicines Agency (Iceland)normalisedTecvayliATCL01FX24REGISTER NO.IS-EU/1/22/1675/002PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Teclistamab is registered in 14 of 19 countries.

Countries holding a registration under ATC L01FX24 (teclistamab), each read from that country’s own register.

  • This record: Iceland, from Icelandic Medicines Agency (Iceland)
  • 9 of them publish a price we can compare per daily dose

Teclistamab · ATC L01FX24

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Icelandic Medicines Agency (Iceland)
Active substance
Teclistamabum INN
Manufacturer
Janssen-Cilag International NV*
Country
Iceland (IS)
ATC code
L01FX24
ATC class
Teclistamab
Defined daily dose
15 mg, P
Reimbursed
Not published by this register
Source register
Icelandic Medicines Agency (Iceland)
Last checked
September 29, 2026

Packs & prices · 1

1 priced
  • ean
    436579
    1,7 ml x1 hgl
    ISK 774435

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Teclistamab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All teclistamab products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Liechtenstein · Tecvayli
  • Norway · Tecvayli

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/9ba23165-88af-440c-94e9-9f57367c1473
GET /v1/drugs/9ba23165-88af-440c-94e9-9f57367c1473?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Stungulyf, lausn",
  "source": "lyfjastofnun",
  "atc_raw": "L01FX24",
  "marketed": true,
  "strength": "90 mg/ml",
  "ma_number": "EU/1/22/1675/002",
  "substance": "Teclistamabum INN",
  "other_info": "Markaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
  "legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
  "ma_issued_serial": "44796"
}

See everything about teclistamab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.